Introduction

Many diseases are being treated with drugs having protein nature. These exogenous proteins having therapeutic role are used as a replacement therapy for self-proteins. These Protein therapeutics are checked and analyzed to maintain biosafety measures and toxicity, viral and bacterial contaminations are removed. Beyond checking these measure there is immune response to a protein drug that is called “immunogenicity” can neutralize the effect of therapeutic cytokine (Barandun and others [1]; Dasgupta and others [2]). The concept was that ‘self’ derived protein therapeutics like recombinant human cytokines IFNβ1-3 IFNα4,5, GM-CSF6 and human anti-TNFα7,8 antibodies will not cause immunogenicity. But there are many examples of recombinant proteins that cause host immune responses directed against the therapeutic (Baker and others [3]; Casadevall [4]; Cassinotti and others [5]). Mostly immunogenic reaction involves anaphylaxis, cytokine release syndrome, and production of antibodies that can cross-react with recombinant cytokine and cause neutralization (Jullien and others [6]; Moussa and others [7]).

Third type of Immunogenicity involves the generation of anti-therapeutic antibodies and activation of both adaptive (involved high affinity, highly specific antibodies and ‘memory’ cells) and non-adaptive (initiated by innate receptors not long-lasting). These responses can be neutralizing and non-neutralizing and involved mostly polyclonal antibodies of multiple isotypes (IgM, IgG and IgE). Antibodies that are produced during these responses have variable region. Because protein therapeutics are derived from endogenous proteins by molecular biology techniques like recombinant human erythropoietin that’s why any immunogenic response towards these proteins can cross-react with the endogenous protein. In this way it results in morbidity and mortality (Baker and others [3]; Casadevall [4]). There are many factors that affect immunogenicity of therapeutic protein products involving patient-related and product-related factors. These factors determine the immunogenicity risk assessment (Jullien and others [6]) Figure 1.

Factors playing a role in causing Immunogenicity

There are many factors that are responsible for causing immunogenicity like a deficiency of T cell and B cell tolerance that is...
resulted due to the absence of the endogenous protein. But immunogenicity can be observed in some patients who already have endogenous proteins. It means other than T and B cell tolerance there are some factors are involved.

Figure 1: Immunogenicity of therapeutic cytokines (Moussa and others [7]).

- **Dose of the therapeutic recombinant cytokine or protein** because every protein or drug should be administered in an appropriate amount otherwise high or low amount can cause immunogenicity (Bee and others [8]; Bellomi and others [9]).
- **Immunologic conditions** status of the patient like if a patient’s immune system is suppressed then there will be less chance of immunogenicity as compared to healthy individual (Jullien and others [6]; Ragnhammar and others [10])
- **Age of the Patient** matters a lot like older individual’s immune system is not as activated as an adult so there will be less chance of immunogenicity (Baker and others [3]).
- **Prior allergy or sensitization** to that therapeutic product or related product results in antibodies production that’s why when these products are administered results in early immunogenic reactions (Jullien and others [6]).
- **Route of administration** also effects immunogenicity like intradermal, subcutaneous, and inhalational routes are considered highly immunogenic as compared to intramuscular and intravenous (IV) routes. The intravenous route is least responsible for immune response (Rosenberg and Worobec [11]).
- **Genetic condition** like HLA of the patient can play a major role in causing immunogenicity (Hoffmann and others [11]).
- **Recombinant therapeutic protein is human or non-human** determine immunogenicity like foreign proteins have more chances of causing immunogenicity as compared to proteins derived from endogenous proteins (Kessler and Ortel [13]). But due to polymorphism these proteins can also immunogenicity (Viel and others [14]).
- **Glycosylation** reduces protein immunogenicity by covering its immunogenic epitopes and reduces protein aggregation (Cole and others [15]; Viel and others [14]).
- **Storing conditions** of the drug like if stored in abnormal conditions then oxidation, reduction, methylation or related damage to the protein can result in immunogenicity (Cleland and others [16]; Morris and others [17]; Wakankar and Borchardt [18]). Potential cytokines, their immunogenic factor and subsequent responses are tabulated in Table 1.

<table>
<thead>
<tr>
<th>Serial number</th>
<th>Factors</th>
<th>Responses</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Cytokine dosage</td>
<td>Increased immunogenicity</td>
<td>(Bee and others 2009; Bellomi and others 2003)</td>
</tr>
<tr>
<td>2</td>
<td>Immune status</td>
<td>Suppressed immunity=Increased immunogenic reactions</td>
<td>(Jullien and others 2015; Ragnhammar and others 1994)</td>
</tr>
<tr>
<td>3</td>
<td>Age</td>
<td>Older age=decreased immunogenicity</td>
<td>(Baker and others 2010)</td>
</tr>
<tr>
<td>4</td>
<td>Sensitization</td>
<td>Early immunogenic reactions</td>
<td>(Jullien and others 2015)</td>
</tr>
<tr>
<td>5</td>
<td>Route of Administration</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Response of body's immunity against protein therapeutics

The first line of defense against protein therapeutics mostly recombinant cytokines involve innate receptor activation with subsequent activation of APCs (antigen presenting cells) e.g. B-cells and dendritic cells (Diebold [19]; Vos and others [20]; Varovinsky and others [21]). These innate receptors present on APCs will in turn activate the adaptive immune response (Adams and others [22]; Medzhitov and Janeway [23]). It has been shown that various functional groups present on drug therapeutics could stimulate the immune system for providing immunogenicity e.g. glycosylation of drugs (Hou and others [24]). This glycosylation make a drug therapeutic unlike 'self' and as a result immune system gets activated against it (De Groot and Scott [25]). The following figure illustrates the activation of adaptive immunity; It has been shown that the protein therapeutics/ cytokines that are aggregated or multimeric in nature shows enhanced immunogenicity as they can enhance humoral immunity more efficiently. It has also been shown that therapeutic recombinant cytokine IFN-α could aggregate in transgenic mice and could raise specific antibodies (Bachmann and others [26]; Braun and others [27]; Rosenberg [28]).

Sometimes, antibodies could preexist in the body derived from the endogenous parts of a therapeutic protein i.e. recombinant cytokine. These occur when the auto reactivity of T/B cells is not screened against the self-proteins. Also, the difference in the protein sequence (cytokine) of natural and recombinant proteins could impart the immunogenicity differently (De Groot and Scott [25]; Marshall and others [29]; Reding and others [30]; Reding and others [31]; Rosenberg [28]). The route of administration influences the immunogenicity of a therapeutic cytokine. Intracellular administrations elicit enhanced immunogenic response as compared to subcutaneous (Schelleken [32]). In case of subcutaneous administration, dendritic cells in epidermis also called as Langerhans cells acts as APC and phagocytize the protein and after that process of antigen presentation pathway takes place (De Groot and Scott [25]; De Smedt and others [33]; Pritchard and Smith [34]; Sparwasser and others [35]).

In case of administered cytokines (mostly intracellular), the first line of defense is MZ (marginal zone) B cells as they are strategically placed in the marginal zone of lymph nodes and spleen (Sauerborn and others [36]). The figure below illustrates the mechanism of immune response activation against recombinant therapeutic cytokines. Apart from these general mechanisms, there are many underlying factors that influences the immunogenicity against recombinant therapeutic cytokines, that remains largely unknown (Hermeling and others [37]).

Ways to reduce immunogenicity

There are many ways to reduce immunogenicity of the therapeutic cytokine or protein is to decrease the number of epitopes for T-cells. This is done by deimmunization and by doing this procedure immunogenicity can be decreased to a great extent (Baker and others [31]). The other way to reduce immunogenicity is to screen the history of allergies of the patient because if he is allergic to that therapeutic protein or related one then immunogenicity will enhance. To select the appropriate route of administration and change it during treatment according to the result will prove effective. Third way is to already check the number or quantity of antibodies in the patient for that therapeutic cytokine. Evaluation of the polymorphism for that protein can be proved very effective as it mismatches or similar to therapeutic recombinant cytokine. It is important to remove all the normal cell related impurities. Protein should be glycosylated as it decreases immunogenicity and storage conditions of the drug should be very maintained and appropriate so that denaturation can’t occur (Galsky and others [38]; Pandit-Taskar and others [39]; Vallabhajosula and others [40]).

Immunogenicity of therapeutic recombinant Interferons

Interferons were first discovered as powerful antiviral agents some 59 years ago. The recombinant IFN-α2a and IFN-α2b first got approval for the treatment of hairy cell leukemia some 50 years ago. Currently these IFNs are used widely for the treatment of viral infections and various types of cancers. IFNs are basically proteins in nature many of which are related both in 3D structure and amino acid sequences. IFNs are categorized into two types; Type I which usually consist of IFN α, β and ω. While as Type II includes INF-Y which are basically produced by activated T-cells and Natural killer cells. On the other hand, IFN -α and ω are produced by leukocytes while IFN -β are the products of fibroblast (Pfeffer and others [41]).

Figure 2.

<table>
<thead>
<tr>
<th>Source</th>
<th>Increased immunogenicity</th>
<th>Decreased immunogenicity</th>
<th>Least immunogenicity</th>
<th>Highly immunogenic</th>
<th>Least immunogenic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intradermal, subcutaneous, inhalational routes</td>
<td>Intravenous routes</td>
<td>Foreign cytokines</td>
<td>Endogenous cytokines</td>
<td>Source</td>
<td>Source</td>
</tr>
<tr>
<td>6</td>
<td>7</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 2: Activation of adaptive immunity (De Groot and Scott [25]).

Recombinant interferons are widely used these days against viral infections. In one such study recombinant human interferon-α-consensus (IFN-Con1) showed greater antiproliferative activity and enhanced natural killer cell killing of target cells than that of IFN-α2a and IFN-α2b, but the antiviral activities of IFN-Con1 were similar to that of IFN-α2a and IFN-α2b. So IFN-Con1 would be significant in low protein concentration than other IFNs for clinical applications (Ozes and others [42]). Another study shows that IFN-Con1 as compared to IFN-α is a lower inducer of IL-1β (Blatt and others [43]).

When three recombinant human interferons naming IFN-α2a, IFN-β and INF-Y were compared in human cultured fibroblast cells against cardiotrophic enterovirus. After few days when a persistent infection was developed IFNs were added. As a result IFN-β and INF-Y showed higher activity and reduced viral load significantly on the contrary IFN-α2a was found to be less effective than the other two interferons (Heim and others [44]). In another research natural IFN-α reduced same amount of viral load at lower concentration as compared to recombinant IFN-α2a (Heim and others [45]).

When the effect of recombinant human leukocyte interferon (IFLrA) on the cytotoxic and cytostatic activity of natural killer cells and monocytes was studied it was found that a very small amount of interferon resulted in high natural killing and monocyte-mediated activity (Herberman and others [46]). In a study on cancer patients when a single dose of IFN-ωrA was injected into cancer patients the cytotoxicity of natural killer cells of all patients declined significantly (Lotzová and others [47]).

In a study two human recombinant IFNs (A&D) along with five of their hybrids containing various portions of A and D were tested along with a fibroblast recombinant IFNs for the modulation of cytolytic activity of NK cells in humans. It was observed in mouse that these interferons caused correlation between antiviral activity and augmentation of mouse NK activity. On the other hand such correlation was not observed in humans Figure 3.

Figure 3: Immune activation by recombinant therapeudeutic proteins.

In a research it was found that there is a selective antiproliferative effect of recombinant human interferons on malignant human myeloid progenitor cells as compared to normal cells (Grant and others [48]; Ortaldo and others [49]). In another such study it was revealed that, in addition to antiviral activity the recombinant human leukocyte interferon produced in E.coli also exhibit antiproliferative activities (Defrance and others [50]; Evinger and others [51]). In a study it was illustrated that recombinant human interferon-gamma act as a B-cell growth factor (BCGF) but this proliferation of B-cell is short lasting as compared to the proliferation induced by recombinant IL-(Defrance and others [50]; Romagnani and others [52]). PCSK6 aid in the cell proliferation, migration, and inflammation in rheumatoid arthritis fibroblast like synoviocytes (RAPS) by activating NF-kB, STAT3 and ERK1/2 signaling pathways (Jiang and others [53]).

As the focus of this article, interferon should be taken into consideration as they are promising for the future. Currently, interferons are being used in viral defense as they generate antiviral state especially against HBV and HCV infections but many studies indicated its adverse effects. For example interferon could induce the
proliferation of pro-inflammatory cytokines like TNF and interleukins which could alter the mechanism and actions of many important metabolic precursors including tryptophan, serotonin etc. The immunogenicity and inflammation also links with depression as serotonin levels are disturbed, many patients have been shown to develop depression (Fried [54]).

It has been observed that aggregated or partially denatured repeated injections of recombinant IFNs, causes decrease in the immune tolerance to self-antigens leads to the to the production of antidrug antibodies (De Santi and others [55]). ADAs cause neutralization of the drug, immune complex disease, allergic reactions and severe autoimmune reactions. IFNs can cause damage by promoting tumor growth because it has observed that IFNg causes resistance to NK cells that results in enhanced metastatic ability and up-regulation of non classical MHC class I molecules that cause inhibition of NK and T cell killing so the assessment of immunogenicity before giving interferon is very necessary [56] Figure 4.

Figure 4: Ways to reduce immunogenicity.

Future perspective

a. Numerous cytokines like TGF-β, CCN2, IFN-α and IFN-β had a great potential for the treatment of connective tissue diseases like Systemic sclerosis (SSc).

b. Recombinant IL-7 has potential role in Tumor-direct Immunotherapy and as an Immunorestorative.

c. TGF-β is predicted to have a great role in engineered organogenesis.

d. Recombinant cytokines will be the key components of future HIV therapies.

e. As interferon shows to be producing adverse effects in patients usually inflammation so restricting the dose of interferon or using interferon in a combination therapy may prevent inflammatory problems associated with the cytokines.

f. Assessment of immunogenicity before giving interferon is very necessary.

References


